1. 25LBA Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) + vemurafenib (VEM) in the phase 3 coBRIM study. (September 2015) Authors: McArthur, G.; Larkin, J.; Dréno, B.; Ascierto, P.; Liszkay, G.; Maio, M.; Mandal´, M.; Demidov, L.; Stroyakovskiy, D.; Thomas, L.; De la Cruz-Merino, L.; Atkinson, V.; Dutriaux, C.; Garbe, C.; Wongchenko, M.; Hsu, J.; Koralek, D.; Rooney, I.; Yan, Y.; Ribas, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S722 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067). (September 2015) Authors: Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J.J.; Cowey, C.L.; Lao, C.D.; Wagstaff, J.; Hogg, D.; Hill, A.; Carlino, M.S.; Wolter, P.; Lebbé, C.; Schachter, J.; Thomas, L.; Hassel, J.C.; Lorigan, P.; Walker, D.; Jiang, J.; Hodi, F.S.; Wolchok, J.D. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S664 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 35MO Number of IL-2 doses and clinical outcomes of tumor-infiltrating lymphocyte (TIL) cell therapy: Post hoc analysis of the C-144-01 trial of lifileucel in patients with advanced melanoma. (December 2022) Authors: Hassel, J.C.; Sarnaik, A.; Chesney, J.; Medina, T.; Hamid, O.; Thomas, S.; Wermke, M.; Domingo-Musibay, E.; Kirkwood, J.M.; Larkin, J.; Weber, J.S.; Arance Fernandez, A.M.; Rodriguez, J.F.; Thomas, I.; Corrie, P.G.; Gontcharova, V.; Wu, X.; Shi, W.; Kluger, H. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 432 Correlative analyses of serum biomarkers and clinical outcomes in the phase 2 study of lenvatinib, everolimus, and the combination, in patients with metastatic renal cell carcinoma following 1 VEGF-targeted therapy. (September 2015) Authors: Glen, H.; Hsieh, J.; Michaelson, M.D.; Kim, H.J.; Sachdev, P.; Kadowaki, T.; Funahashi, Y.; Larkin, J.; Motzer, R. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S89 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 87P Infliximab use in patients with checkpoint inhibitor toxicities: A tertiary centre experience. (December 2022) Authors: Zhang, S.H.; Cartwright, E.; Mullings, S.; Ferro Lopez, L.F.; Cunningham, D.; Chau, I.; Starling, N.; Popat, S.; O'Brien, M.E.R.; Bhosle, J.; Minchom, A.R.; Davidson, M.; Tokaca, N.; Lalondrelle, S.; Pickering, L.M.; Furness, A.; Turajlic, S.; Larkin, J.; José, R.; Young, K. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. (6th March 2016) Authors: Spain, L.; Higgins, R.; Gopalakrishnan, K.; Turajlic, S.; Gore, M.; Larkin, J. Journal: Annals of oncology Issue: Volume 27:Number 6(2016:Jun.) Page Start: 1135 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Baseline characteristics of the applied public-private research enabling osteoarthritis clinical headway (approach) cohort. Issue 1 (April 2020) Authors: van Helvoort, E.M.; Jansen, M.P.; Welsing, P.M.; Kloppenburg, M.; Loef, M.; Blanco, F.J.; Haugen, I.K.; Berenbaum, F.; Bacardit, J.; Ladel, C.; Loughlin, J.; Bay-Jensen, A.-C.; Mobasheri, A.; Larkin, J.; Boere, J.; Weinans, H.; LaLande, A.; Marijnissen, A.C.; Lafeber, F.P. Journal: Osteoarthritis and cartilage Issue: Volume 28:Issue 1(2020)supplement Page Start: S367 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Beyond Teenage and Young Adult Cancer Care: Care Experiences of Patients Aged 25–39 Years Old in the UK National Health Service. Issue 8 (August 2021) Authors: Lidington, E.; Darlington, A.S.; Vlooswijk, C.; Beardsworth, S.; McCaffrey, S.; Tang, S.; Stallard, K.; Younger, E.; Edwards, P.; Ali, A.I.; Nandhabalan, M.; Din, A.; Starling, N.; Larkin, J.; Stanway, S.; Nobbenhuis, M.; Banerjee, S.; Szucs, Z.; Gonzalez, M.; Sirohi, B. Journal: Clinical oncology Issue: Volume 33:Issue 8(2021) Page Start: 494 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Clinical resolution of vemurafenib‐induced squamous cell carcinoma with topical 5‐fluorouracil. (1st April 2015) Authors: Sinha, R.; Larkin, J.; Fearfield, L. Journal: British journal of dermatology Issue: Volume 172:Number 4(2015:Apr.) Page Start: 1135 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Clinical resolution of vemurafenib‐induced squamous cell carcinoma with topical 5‐fluorouracil. (26th February 2015) Authors: Sinha, R.; Larkin, J.; Fearfield, L. Journal: British journal of dermatology Issue: Volume 172:Number 4(2015:Apr.) Page Start: 1135 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗